Sticking with the plan and follow-up with a doctor helps track progress
Post Log inSign up Post Hims House @himshouse ELI LILLY TO FILE RETATRUTIDE FDA APPROVAL APPLICATION IN Q1 2027 PREVIOUSLY SOME SPECULATION THIS WOULD HAPPEN BY EOY 2026 $LLY $NVO $HIMS 12:32 PM Jul 23, 20268KViews Arthritisfinger @arthritisfinger Jul 23 $HIMS is by far the strongest partner of Novo Lilly needs $HIMS desperately RAWDII @RAWDII3 Jul 23 Please go to hell Eli Lilly Join the conversation Read 3 more replies
The primary composite endpoint (cardiovascular death or worsening heart failure) was reached in 9,9% of the tirzepatide arm versus 15,3% of the placebo arm (HR 0,62, p=0,026)
Staying hydrated is crucial when taking GLP-1 medications, as they can significantly reduce thirst and slow digestion
Amgen is developing maridebart cafraglutide, known as MariTide, a long-acting peptide-antibody conjugate designed to increase GLP-1 receptor activity while inhibiting GIP receptor activity
Gentle guidance for patients and physicians If you are a physician or other clinician with a patient tempted by that Subscribe Now button, or a patient yourself, pause for a breath and ask four things: Does the service ship factory-sealed pens